Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

Esophageal cancer starts with subtle symptoms like trouble swallowing, heartburn, and hoarseness, but early detection is ...

Jose B. Lingad Memorial General Hospital Head and Neck Cancer Specialist Paulyn Gaddi urges the public to practice healthy ...

ABSTRACT: Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor with a unique geographical distribution, predominantly prevalent in East Africa and Asia. Despite advances in understanding its ...

Comedian Milton Jones has postponed the rest of his tour after being diagnosed with prostate cancer and being scheduled for surgery. Prostate cancer has become the country's most common cancer, after ...

prostate cancer won’t give you symptoms in its crucial early stages when it’s easier to treat, so as a charity we can’t tell you about tell-tale signs to look out for. “That’s why we do ...

She now has to be checked regularly for the rest of her life to make sure the cancer doesn’t come back. She believes that because her symptoms were not the usual signs of Hashimoto’s disease, doctors ...

coli may set the stage for colon cancer later in life. Common symptoms include blood in the stool and abdominal pain, which are most often caused by more benign conditions like hemorrhoids ...

To be marked as Anniko, penpulimab is approved alongside chemotherapy for the first-line treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma, or as a single agent in ...

in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab ...

The antibody is to treat adult recurrent or metastatic non-keratinising nasopharyngeal carcinoma (NPC) in conjunction with cisplatin or carboplatin and gemcitabine as a first-line treatment.

in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved ...